LMG
0.014
40%
OVT
0.001
-50%
PNT
0.007
40%
IBR
0.023
-48.9%
ARO
0.004
33.3%
BRY
0.013
-31.6%
NH3
0.125
31.6%
BGE
0.01
-23.1%
SLB
0.32
25.5%
AM3
0.004
-20%
LIB
0.005
25%
DWG
0.12
-20%
SRJ
0.005
25%
RPM
0.012
-20%
CYB
0.051
21.4%
EXT
0.005
-16.7%
PL9
0.006
20%
H3E
0.005
-16.7%
RCL
0.06
20%
MHC
0.021
-16%
PLC
0.007
16.7%
ADN
0.006
-14.3%
HMG
0.25
16.3%
AVW
0.006
-14.3%
DM1
0.008
14.3%
AX8
0.006
-14.3%
OD6
0.125
13.6%
NS1
0.006
-14.3%
AMD
0.017
13.3%
XST
0.012
-14.3%
AUR
0.017
13.3%
IMC
0.044
-13.7%
EMD
0.053
12.8%
CGR
0.064
-13.5%
IVZ
0.071
12.7%
VRS
0.04
-13%
GTE
0.009
12.5%
A8G
0.175
-12.5%
RON
0.18
12.5%
PCL
0.007
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf